---
title: Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed
  multiple myeloma treated within the GMMG-MM5 phase III trial
date: '2024-02-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38407192/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240226170504&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'OBJECTIVES: The seroprevalence of antibodies against Cytomegalovirus
  (CMV) is an established poor prognostic factor for patients receiving an allogeneic
  stem cell transplantation. However, the impact of CMV serology on outcome after
  autologous stem cell transplantation remains ...'
disable_comments: true
---
OBJECTIVES: The seroprevalence of antibodies against Cytomegalovirus (CMV) is an established poor prognostic factor for patients receiving an allogeneic stem cell transplantation. However, the impact of CMV serology on outcome after autologous stem cell transplantation remains ...